

Real LifeTM

Rosa Canet-Avilés, PhD

Vice President, Scientific Programs and Education

Abla Creasey, PhD

Vice President, Therapeutics Development

Science Subcommittee - November 30, 2023

CIRM
CALIFORNIA'S STEM CELL AGENCY

OUR MISSION

Accelerating world class science
to deliver transformative
regenerative medicine treatments
in an equitable manner to a
diverse California and world



Proposed DISC0 and DISC2 Concept Amendments

Rosa Canet-Avilés, PhD

Vice President, Scientific Programs and
Education



DISCOVERY Pillar Programs



DISCOVERY



TRANSLATION



CLINICAL

Foundational Knowledge



Single Product Candidate



Pre-IND Meeting or Equivalent



Approved Therapy



DISC0
FOUNDATION
AWARDS

DISC2
QUEST
AWARDS

TRAN1/2/3/4
AWARDS

CLIN1/2
AWARDS

DISC4
ReMIND
AWARDS

1. Award Tracks

2. Award Budgets



Rationale

- Tool/Device development and proof of concept is already supported by DISC0 mechanism
- Biomarker track: Includes Diagnostic + Expands scope to high unmet need in Tx Dev of Regenerative Medicine treatments (and CNS diseases)



* Direct project costs for entire award

Rationale


- Increased award accounts for higher costs of trainees/research
- \$200K special supplement expanded to all therapeutic applications via higher base budget
- Budget and duration for biomarker track comparable to similar awards

- 1. Award Tracks**
- 2. Award Budgets**
- 3. PI Percent Effort**



Rationale

- Team track will support synergistic, multidisciplinary collaborations with larger scope
- Teams drive innovation, creativity, and risk-taking with the support of a group



Rationale

- Budget increased to account for higher costs of trainees/research
- Budget and duration in line with similar awards for Team Track
- New support for collaborative team track (PI + 1-2 Co-I)

DISCO Awards: Changes in Percent Effort

Current % Effort	Proposed % Effort *
<p>Single PI Track</p> <ul style="list-style-type: none">• PI – 20%	<p>Single PI Track</p> <ul style="list-style-type: none">• PI – 15% <p>Team Track</p> <ul style="list-style-type: none">• PI – 15%• Co-Is – 10%

Rationale

- Board feedback/alignment with other funding bodies

CIRM requests the committee recommend to the ICOC approval of these amendments



Proposed CLIN Concept Amendments and CLIN4 Concept Proposal

Abla Creasey, PhD

Vice President, Therapeutics Development



What is CIRM recommending?

- 1. Remove clinical track for medical devices**
- 2. Increase maximum award amounts for CLIN1**
- 3. Update CLIN2 PA to highlight specific allowable activities for product development**
- 4. Introduce new CLIN4 PA to fund Late-Stage Development activities necessary to file a BLA and readiness for product launch**

Clinical Programs Awards Overview



Aim / Scope

Eligibility

Duration

CLIN 1

IND Enabling

Pre-IND Meeting
/ Start in 45 Days

24 Months*

CLIN 2

Clinical Trial

Active IND / Start
in 45 Days

48 Months

CLIN 4

BLA Enabling


Active CLIN2 /End
Of Phase 2 mtg

48 Months

* Up to 6 months additional for start-up activities

CLIN1 Awards: Changes in Award Amount

Maximum total CIRM award amount



Rationale

- Increased award amounts accounts for toxicology studies, manufacturing, and higher workers wages costs
- Duration for CLIN 1 remains at 24 months

Recommended CLIN2 Concept Changes

Why are changes needed?

- When CLIN2 was implemented, most CIRM-funded trials were in **Early-stage** Clinical Development
 - Phase 1 or Phase 2
- As the field has matured, more programs are entering **Late-stage** Development
 - Phase 3 or Pivotal/registration trial stage directly from phase 1/2 dependent on the disease indication
- The current CLIN2 Program Announcement is not clear or explicit about the support of specific late-stage development activities
- To Ensure Best Practices Alignment with the FDA

Clarification of Eligible Activities in CLIN2

Activities that qualify for funding under CLIN2:

- Compilation of **alternative comparator data** acceptable to FDA for a marketing approval decision and intended to support the proposed interventional clinical trial in cases where placebo or sham controls are not possible.
 - Examples include **Natural History studies** or use of existing **data repositories**
 - Must have documented FDA agreement on the acceptability of the proposed comparator
- Compilation of **Patient-Reported Outcomes (PRO)** related to the conduct of the proposed trial
- Compilation of **Real -World Data (RWD)** and **Real- World Evidence (RWE)** related to the conduct of the proposed trial
- Activities that support **DEI** goals described in the proposal

What is the purpose of a CLIN4?

- Certain key activities required by FDA to get to **Biologics License Application (BLA)** filing and readiness for product Launch are not covered by the current CLIN2 PA
- The goal of a CLIN4 is to support CIRM-funded programs to achieve a **BLA filing** and advancement towards the goal of obtaining marketing approval
- Logical bridge to AAWG; demonstrating CIRM's commitment to Access & Affordability

Who is 'new' CLIN4 for?

Eligibility Criteria:

- Must have an **active CLIN2 award**
- Must have completed 50% of milestones of an active CLIN2 award
- Must have completed an **End-Of-Phase 2 meeting or equivalent** with FDA and have **concurrence** on requirements for a BLA filing

What will 'new' CLIN4 provide?

- Up to **\$12M** to cover **Late-Stage Development activities** necessary for BLA filing but not included in the CLIN2 award

Late-Stage Development Activities that may be Funded under CLIN4:

- Activities necessary for **filing a BLA** such as:
 - conduct of a Pre-BLA meeting with FDA
 - compilation of an electronic common technical document (eCTD)
- **Product manufacturing** activities necessary to submit a BLA
- **Commercial development** activities such as pharmacoeconomic analysis, budget impact models (managed health-payer perspective)
- Development of a **supply chain** strategy
- Initiation of **pre-commercialization activities** such as production of a Payors' cost-effectiveness Analysis Report, compilation of an AMCP Dossier
- **Compassionate use** of the investigational therapy for patients in the period after enrollment closed and Market Approval is awarded with FDA approval and agreement with the drug product supplier

Clinical Programs Awards Overview



Aim / Scope

Eligibility

Duration

\$\$

CLIN 1

IND Enabling

Pre-IND Meeting / Start in 45 Days

24 Months*

6M to 7M**
4M to 5M

CLIN 2

Clinical Trial

Active IND / Start in 45 Days

48 Months

15M

CLIN 4

BLA Enabling

Active CLIN2 /End of Phase 2 Mtg

48 Months

12M

- Up to 6 months additional for start-up activities
- ** \$7M for Non- profit; \$5M for Profit

CIRM requests the committee recommend to the ICOC approval of these amendments and the CLIN4 concept plan